Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

- PMLiVE

Digital mania – a question of value

In the scramble to implement digital solutions, are we forgetting some of the basics?

- PMLiVE

Ex-GSK CEO Witty named head of pharmacy benefit firm Optum

Current Optum CEO Larry Renfro will move to Optum Ventures as MD

- PMLiVE

Getting in the LUCID SPIRIT!

Lucid Group launches charity partnership with Wycombe Homeless Connection

Lucid Group Communications Limited

- PMLiVE

AbbVie’s uterine fibroids drug aces second phase III trial

An FDA verdict is expected in the US in the coming weeks

Speech therapy

In 2002 an MIT scientist named Timothy Bickmore recruited 91 students to a study in a field of research that he later dubbed ‘patient-centric computing.’Over 30 days, two groups of...

Biogen Idec building

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

- PMLiVE

Long-serving R&D head Bischofberger to leave Gilead

John McHutchison, currently executive VP of clinical research, will step into the role

Innovative NHS suppliers scoop HSJ Partnership Awards

Winners include pharma, medtech, healthcare consultants and IT specialists. Innovative pharma and medtech companies have been honoured in an awards scheme run by Health Service Journal (HSJ), the news and...

Wilmington Healthcare

- PMLiVE

Communication is the key to the participatory medicine model

Participatory medicine is an emerging healthcare movement that champions patient preference and values as equal to medical expertise. Following participatory medicine processes means that everyone involved in a healthcare decision...

- PMLiVE

Rapid career progression at Porterhouse Medical

We are delighted to announce another promotion within our scientific services team.

Porterhouse Medical Group

Sanofi reception

Sanofi, Regeneron offer price cut for cholesterol drug Praluent

Amgen’s Repatha also struggled to secure reimbursement at its launch price point

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links